AML blasts with RUNX1mut demonstrated synthetic lethality in a combination approach with omacetaxine mepesuccinate and venetoclax, perhaps partly owing to the omacetaxine-related repression of MCL1, an antiapoptotic protein commonly implicated in venetoclax resistance [85,86]. The gene discussed is MCL1; the disease is acute myeloid leukemia.